Guest Columns

  1. Can Regulation (Really) Encourage Innovation? The FDA, Continuous Manufacturing, & Patient Safety
    11/21/2017

    A diverse group of industry veterans discuss ways in which the FDA encourages innovation, what role the agency’s Emerging Technology Team (ETT) plays in supporting manufacturing innovation, and whether the regulator’s innovation-safety balance is (or should be) the same for rare or orphan disease treatments as it is for blockbuster drugs.

  2. 7 Surefire Ways To Motivate A Life Science Consultant
    11/17/2017

    Consultants play a significant role in the pharmaceutical, biopharmaceutical, vaccine, and medical device industries. They are experienced resources in crisis situations; when new facilities are being installed; under circumstances requiring technical expertise; and during regulatory emergencies, remediations, consent decrees, and other planned and unplanned situations. Problems often occur between clients and consultants, and both contribute to them. Motivational enablers/drivers increase the probability that a project will be completed successfully, provided the consultant acquires their own motivational abilities coupled with experience that meets the project requirements.

  3. CMS’ Decision On Coding For Biosimilars: A Deeper Look
    11/16/2017

    The November 2017 decision by CMS to change the coding practice for biosimilars in the United States is likely to have far-reaching consequences for these drugs, but will all downstream effects be positive? As the decision is applauded by various prescriber, patient, and industry groups, it is key to investigate the events that could ensue from the decision, and whether it will stimulate the U.S. biosimilar industry, which languishes behind that of other geographies.

  4. Emerging Best Practices For Contamination Management In Pharmaceutical Manufacturing
    11/15/2017

    Despite quality audits and third-party oversight, contamination of prescription and over-the-counter (OTC) pharmaceutical products is still prevalent. This is despite the adoption of cGMP practices, SOPs, risk mitigation methods, and metrics such as key performance indicators. We evaluated various emerging practices to overcome contamination issues. Novel batch concentration tests and dedicated capacity utilization have proven to overcome the source of contaminants. For technology adoption in continuous manufacturing, which is unclear in terms of compliance, the FDA Emerging Technology Team could be used for advisory oversight.

  5. The Complex Litigation Surrounding Remicade And Its Biosimilar Challengers
    11/14/2017

    Control of the Remicade and biosimilar market is being aggressively contested by Janssen, J&J, Celltrion, Hospira, and Pfizer. This article discusses the legal issues being decided in each of the federal court cases surrounding Remicade.

  6. Selecting A CDMO: Strategies To Ensure A Successful Partnership
    11/14/2017

    The story is a common one. Your organization has just acquired a new asset and you are responsible for finding the custom development and manufacturing organization (CDMO) that is going to take you all the way to commercialization. The hard part is over, right?  If only it were that simple.  The process of selecting your partner is more than just drafting an agreement; it is a complex give and take that relies on clear expectations and communication.

  7. Big Data Vs. Small Data: What’s The Proper Prescription For You?
    11/13/2017

    This article will explain what Big Data and small data are, build your fluency with the benefits and risks of each, and provide recommendations to improve our data-rich future.

  8. When And How To Implement Data Integrity Practices In The Product Development Lifecycle
    11/10/2017

    Data integrity is frequently discussed in many industries. It is more formally defined within the life sciences industry through regulation (e.g., current good manufacturing practices [cGMPs], good laboratory practices, good clinical practices, the application integrity policy) and in guidance documents from health agencies, including the FDA and WHO. These regulations set the expectations for companies to ensure data integrity and traceability by establishing and monitoring the effectiveness of their quality systems.

  9. Tech Transfer Project Management Best Practices
    11/7/2017

    When I first became a project manager, it did not take long to realize the pain associated with a lack of resource availability and cross-functional cooperation. This includes a lack of direct project support from functional areas and having the project work low on their priority lists. There simply had to be a better way for the teams to succeed.  A few years later, I became a PMP (project management professional) and then grew into the manger of project management role.

  10. How India Cultivated A Thriving Biosimilar Ecosystem
    11/7/2017

    Although the biosimilar space is still growing and evolving in the U.S., it is comparatively well-established in India. According to the Generics and Biosimilars Initiative (GaBI), the first “similar biologic” was approved and marketed in India in 2000 — some 15 years before the U.S. approved its first biosimilar. India also has a much more mature biosimilar manufacturing ecosystem and regulatory environment than most other parts of the world. As such, the country can provide valuable lessons about what it takes to establish a thriving biosimilar market in terms of accessibility, competition, regulatory strategy, and other facets.